$EIGR FDA approval is nice but the Rare Pedriatic Disease Voucher (PRV) is even bigger. It can be sold to another company and can fetch anywhere from $60M - $300M. This program is expiring on Dec. 11 so this voucher can incite a bidding contest among a handful of big pharma. Also, when $KZIA got the rare pedriatic designation on Aug. 7, its sp went up 91% intraday. And this is without the voucher yet, just designation.